疫苗非特异性效应对新疫苗许可的影响
本综述探讨训练免疫作为疫苗诱导非特异性效应的机制,以及这些效应对国家药品监管机构在新疫苗许可时整体风险-获益评估的影响。表观遗传重塑和先天免疫细胞代谢重编程被提示为训练免疫的机制。卡介苗、麻疹疫苗和口服脊髓灰质炎疫苗的非特异性效应已在流行病学研究中广泛记录,但其他疫苗是否类似尚不清楚。
要点
- 训练免疫或先天免疫记忆可由疫苗接种诱导,产生非特异性效应。
- 表观遗传重塑和细胞代谢重编程被提示为训练免疫的机制。
- 已知非特异性效应来自许可后流行病学研究,对新疫苗许可评估有影响。
核心结论
- 疫苗非特异性效应可能影响国家药品监管机构在新疫苗许可时的整体风险-获益评估。
- 在新疫苗临床开发阶段早期识别非特异性效应是否有助于许可评估,尚待观察。
研究设计与样本
- 本综述聚焦训练免疫作为疫苗诱导非特异性效应的机制、训练免疫的潜在机制及已知的疫苗非特异性效应。
- 综述还讨论了这些非特异性效应对国家药品监管机构在新疫苗许可时整体风险-获益评估的可能影响。
主要发现
- 表观遗传重塑和先天免疫细胞(尤其是单核细胞、巨噬细胞和自然杀伤(NK)细胞)的细胞代谢「重编程」被提示为训练免疫的机制。
- 其他先天免疫细胞中的训练免疫迄今仍 largely 未明确。
- 卡介苗(BCG)、麻疹疫苗和口服脊髓灰质炎疫苗的非特异性效应已被广泛记录,但其他疫苗是否可能表现出类似效应仍不清楚。
- 所有已知的疫苗非特异性效应均来自疫苗许可和目标人群推广后开展的流行病学研究的观察。
临床怎么用
- 原文未据此给出推荐。
局限性
- 其他先天免疫细胞中的训练免疫迄今仍 largely 未明确。
- 其他疫苗是否可能表现出类似非特异性效应仍不清楚。
- 所有已知疫苗非特异性效应均来自许可后流行病学研究的观察。
- 早期识别非特异性效应是否有助于许可评估尚待观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune memory was for a long time thought to be an exclusive feature of the adaptive immune system. Emerging evidence has shown that the innate immune system may exhibit memory which has been termed as trained immunity or innate immune memory. Trained immunity following vaccination may produce non-specific effects leading to reduction in morbidity and mortality from heterologous pathogens. This review looked at trained immunity as a mechanism for vaccine induced non-specific effects, mechanisms underlying trained immunity and known vaccine non-specific effects. A discussion is also made on the implications these vaccine non-specific effects may have on overall risk-benefit ratio evaluation by National Medicines Regulatory Authorities (NMRAs) during licensure of new vaccines. Epigenetic remodeling and "rewiring" of cellular metabolism in the innate immune cells especially monocytes, macrophages, and Natural Killer (NK) cells have been suggested to be the mechanisms underlying trained immunity. Trained immunity in other innate cells has largely remained elusive up to date. Non-specific effects have been extensively documented with Bacille Calmette-Guerin (BCG), measles vaccine and oral polio vaccine but it remains unclear if other vaccines may exhibit similar effects. All known vaccine non-specific effects have come from observations in epidemiological studies conducted post-vaccine licensure and roll out in target populations. It remains to be seen if early identification of non-specific effects especially those with protective benefits during the clinical development of new vaccines may contribute to the overall risk-benefit ratio evaluation during licensure by NMRAs.
引用
- Munkwase G. Implications of vaccine non-specific effects on licensure of new vaccines. Vaccine. 2024. PMID: 38242737. doi:10.1016/j.vaccine.2024.01.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。